Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis
Primary result · eGFR-creatinine change from baseline (LS mean)Result — go to the resultBetween-group difference 1.4 mL/min/1.73 m² 95% CI 0.3–2.4Authors' conclusion
Tirzepatide slows the eGFR decline rate, supporting a kidney-protective effect.
Study context
- Population
- Adults with T2D and high cardiovascular risk (SURPASS-4)
- Comparison
- Pooled tirzepatide vs titrated insulin glargine
- Primary endpoint
- eGFR change from baseline
- Follow-up
- 52 weeks
Primary result
eGFR-creatinine change from baseline (LS mean)
Between-group difference
1.4 mL/min/1.73 m²
95% CI 0.3–2.4
Change by group
Tirzepatide
−2.5
least squares mean · SE 0.38 · mL/min/1.73 m²
Insulin glargine
−3.9
least squares mean · SE 0.38 · mL/min/1.73 m²
Tirzepatidevs Insulin glargine
between-group difference 1.4 mL/min/1.73 m² (95% CI 0.3–2.4)
As reported in the abstract
Further findings
Least squares mean, mL/min/1.73 m²
| Outcome | Tirzepatide | Insulin glargine | Between-group difference (mL/min/1.73 m²) (95% CI) | |
|---|---|---|---|---|
| eGFR-cystatin C change from baseline (LS mean) · 52 weeks | −3.5 (SE 0.37) | −5.3 (SE 0.37) | 1.8 (0.8–2.8) | |
| −2024Difference, mL/min/1.73 m² (linear scale) |
Correlation of estimated glomerular filtration rate (eGFR)-cystatin C and eGFR-creatinine
- Baseline, 1-year, and 1-year change values significantly correlated between eGFR-cystatin C and eGFR-creatinine
- eGFR changes did not correlate with body weight changes
Original publication
Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis. Diabetes Care. Published 2 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →